Study design and participants
PTCL-NOS, ALK-negative ALCL
CENTRAL NERVOUS SYSTEM DISEASE
PTCL13 was an open-label, multicenter phase Ib/II trial, that was conducted in 26 Italian centers of the Fondazione Italiana Linfomi. Eligible patients were aged 18–65 years and had untreated PTCL-NOS, angioimmunoblastic/T follicular helper (AITL/THF) and ALK-negative ALCL without central nervous system disease. A detailed list of inclusion and exclusion criteria is provided in the The trial was conducted in accordance with the Declaration of Helsinki and good clinical practice guidelines. Ethical approval was obtained by institutional review boards at each site. All participants provided written informed consent. This trial was registered with ClinicalTrials.gov, number NCT02223208.